In 2025, three major prospective studies shaped the field of venous thromboembolism (VTE) in angiological practice. The ADJUST-DVT study aimed to validate the use of age-adjusted D-dimer thresholds to diagnose deep vein thrombosis, following the already-established strategy for pulmonary embolism. The COBRRA trial was the first prospective study to compare the safety and efficacy of apixaban versus rivaroxaban in the treatment of acute VTE. Finally, the API-CAT study investigated extended anticoagulation in cancer-associated VTE, assessing the long-term use of reduced-dose apixaban as an alternative to full-dose therapy to minimize the risk of bleeding.